Crosshair Therapeutics
Crosshair Therapeutics develops DNA-based therapeutics that target previously intractable disease proteins to expand treatment options in oncology, aging, and other high‑need indications. The company combines machine learning-driven computational design with a proprietary high‑precision protein‑targeting platform and precision drug delivery technologies to generate novel therapeutic candidates. It operates as a biotechnology drug developer and platform company advancing preclinical and translational pipelines and engaging with pharmaceutical partners for development. Crosshair positions its platform to scale against difficult molecular targets and integrate into existing drug discovery workflows.
Crosshair Therapeutics
Crosshair Therapeutics develops DNA-based therapeutics that target previously intractable disease proteins to expand treatment options in oncology, aging, and other high‑need indications. The company combines machine learning-driven computational design with a proprietary high‑precision protein‑targeting platform and precision drug delivery technologies to generate novel therapeutic candidates. It operates as a biotechnology drug developer and platform company advancing preclinical and translational pipelines and engaging with pharmaceutical partners for development. Crosshair positions its platform to scale against difficult molecular targets and integrate into existing drug discovery workflows.